Halozyme Financial Statements (HALO)
|
|
|
|
Report date
|
|
|
31.12.2022 |
21.02.2023 |
20.02.2024 |
18.02.2025 |
17.02.2026 |
|
17.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
660.1 |
660.1 |
829.3 |
1 015 |
1 397 |
|
1 397 |
|
Operating Income, bln rub |
|
|
267.5 |
267.5 |
337.6 |
551.5 |
816.3 |
|
816.3 |
|
EBITDA, bln rub |
? |
|
315.5 |
315.5 |
451.9 |
656.5 |
904.3 |
|
964.3 |
|
Net profit, bln rub |
? |
|
202.1 |
202.1 |
281.6 |
444.1 |
316.9 |
|
316.9 |
|
|
OCF, bln rub |
? |
|
240.1 |
240.1 |
388.6 |
479.1 |
651.6 |
|
651.6 |
|
CAPEX, bln rub |
? |
|
4.81 |
4.81 |
15.3 |
10.7 |
6.97 |
|
6.97 |
|
FCF, bln rub |
? |
|
235.3 |
235.3 |
373.3 |
468.4 |
644.6 |
|
644.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
253.3 |
253.3 |
299.3 |
304.4 |
274.9 |
|
328.2 |
|
Cost of production, bln rub |
|
|
139.3 |
139.3 |
192.4 |
159.4 |
305.4 |
|
252.2 |
|
R&D, bln rub |
|
|
66.6 |
66.6 |
76.4 |
79.0 |
81.5 |
|
81.5 |
|
Interest expenses, bln rub |
|
|
16.9 |
16.9 |
18.8 |
18.1 |
18.1 |
|
18.1 |
|
|
Assets, bln rub |
|
|
1 842 |
1 842 |
1 733 |
2 063 |
2 525 |
|
2 525 |
|
Net Assets, bln rub |
? |
|
169.8 |
169.8 |
83.8 |
363.8 |
48.8 |
|
48.8 |
|
Debt, bln rub |
|
|
1 506 |
1 506 |
1 499 |
1 506 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
362.8 |
362.8 |
336.0 |
596.1 |
142.8 |
|
142.8 |
|
Net debt, bln rub |
|
|
1 143 |
1 143 |
1 163 |
909.7 |
-142.8 |
|
-142.8 |
|
|
Ordinary share price, rub |
|
|
56.9 |
56.9 |
37.0 |
47.8 |
67.3 |
|
64.6 |
|
Number of ordinary shares, mln |
|
|
136.8 |
136.8 |
131.9 |
126.8 |
119.8 |
|
117.7 |
|
|
Market cap, bln rub |
|
|
7 786 |
7 786 |
4 876 |
6 064 |
8 065 |
|
7 596 |
|
EV, bln rub |
? |
|
8 930 |
8 930 |
6 039 |
6 973 |
7 922 |
|
7 453 |
|
Book value, bln rub |
|
|
-786 |
-786 |
-806 |
-455 |
-1 513 |
|
-1 513 |
|
|
EPS, rub |
? |
|
1.48 |
1.48 |
2.13 |
3.50 |
2.64 |
|
2.69 |
|
FCF/share, rub |
|
|
1.72 |
1.72 |
2.83 |
3.69 |
5.38 |
|
5.48 |
|
BV/share, rub |
|
|
-5.74 |
-5.74 |
-6.11 |
-3.59 |
-12.6 |
|
-12.9 |
|
|
EBITDA margin, % |
? |
|
47.8% |
47.8% |
54.5% |
64.7% |
64.8% |
|
69.0% |
|
Net margin, % |
? |
|
30.6% |
30.6% |
34.0% |
43.7% |
22.7% |
|
22.7% |
|
FCF yield, % |
? |
|
3.02% |
3.02% |
7.66% |
7.72% |
7.99% |
|
8.49% |
|
ROE, % |
? |
|
119.0% |
119.0% |
336.0% |
122.1% |
649.2% |
|
649.2% |
|
ROA, % |
? |
|
11.0% |
11.0% |
16.2% |
21.5% |
12.5% |
|
12.5% |
|
|
P/E |
? |
|
38.5 |
38.5 |
17.3 |
13.7 |
25.5 |
|
24.0 |
|
P/FCF |
|
|
33.1 |
33.1 |
13.1 |
12.9 |
12.5 |
|
11.8 |
|
P/S |
? |
|
11.8 |
11.8 |
5.88 |
5.97 |
5.77 |
|
5.44 |
|
P/BV |
? |
|
-9.91 |
-9.91 |
-6.05 |
-13.3 |
-5.33 |
|
-5.02 |
|
EV/EBITDA |
? |
|
28.3 |
28.3 |
13.4 |
10.6 |
8.76 |
|
7.73 |
|
Debt/EBITDA |
|
|
3.62 |
3.62 |
2.57 |
1.39 |
-0.16 |
|
-0.15 |
|
|
R&D/CAPEX, % |
|
|
1 385% |
1 385% |
499.3% |
739.0% |
1 169% |
|
1 169% |
|
|
CAPEX/Revenue, % |
|
|
0.73% |
0.73% |
1.84% |
1.05% |
0.50% |
|
0.50% |
|
| Halozyme shareholders |
